Clinical trial: Peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation

F. Lodato, S. Berardi, A. Gramenzi, G. Mazzella, M. Lenzi, M. C. Morelli, M. R. Tame, F. Piscaglia, P. Andreone, G. Ballardini, M. Bernardi, F. B. Bianchi, M. Biselli, L. Bolondi, M. Cescon, A. Colecchia, A. D'Errico, M. Del Gaudio, G. Ercolani, G. L. GraziW. Grigioni, S. Lorenzini, A. D. Pinna, M. Ravaioli, E. Roda, C. Sama, M. Vivarelli

Research output: Contribution to journalArticle

Abstract

Background: Treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) is difficult with low response rates. Aim: To assess the safety and efficacy of pegylated-interferon (PEG-IFN) alfa-2b + ribavirin (RBV) in patients with post-LT recurrent genotype-1 HCV and to establish stopping rules according to response. Methods: Fifty-three patients with post-LT HCV recurrence were enrolled. Patients received PEG-IFN alfa-2b 1.0 μ/kg/week plus RBV 8-10 mg/kg/day for 24 weeks. Those with 'early virological response at week 24' (EVR24) continued treatment for 24 weeks (group A). Patients without EVR24 were randomized to continue (group B) or to discontinue (group C). Results: Overall sustained virological response (SVR) was 26% (14/53). Alanine aminotransferase, rapid virological response, EVR12, EVR24, undetectable serum HCV-RNA at weeks 12 (cEVR12) and 24 (cEVR24) were related to SVR. cEVR12 and cEVR24 (OR: 14.7; 95% CI: 2.02-106.4) were independent predictors of SVR. All patients with SVR, had cEVR12. No patient in groups B and C achieved end-of-treatment response. One patient in group B had SVR. Conclusions: Pegylated-interferon alfa-2b was effective in one of four of patients with HCV genotype 1 after LT. Treatment should be discontinued in patients with no virological response at week 12. Further studies are needed to evaluate whether a longer treatment period may be beneficial in patients with ≥2 log 10 drop in HCV-RNA at week 24.

Original languageEnglish
Pages (from-to)450-457
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume28
Issue number4
DOIs
Publication statusPublished - Aug 2008

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Lodato, F., Berardi, S., Gramenzi, A., Mazzella, G., Lenzi, M., Morelli, M. C., Tame, M. R., Piscaglia, F., Andreone, P., Ballardini, G., Bernardi, M., Bianchi, F. B., Biselli, M., Bolondi, L., Cescon, M., Colecchia, A., D'Errico, A., Del Gaudio, M., Ercolani, G., ... Vivarelli, M. (2008). Clinical trial: Peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Alimentary Pharmacology and Therapeutics, 28(4), 450-457. https://doi.org/10.1111/j.1365-2036.2008.03761.x